Mammals have evolved an interconnected molecular and cellular network of nucleic-acid sensors to rapidly respond to incoming viruses and bacteria 1, 2 . Sentinel cells of the hematopoietic system, predominately macrophages and dendritic cells (DCs), are distributed throughout the body and express Toll-like receptors (TLRs) that recognize the nucleic acids carried by pathogens 2, 3 . Such sensors represent the first line of defense against pathogen invaders.
TLR7 and TLR9 are triggered by their pathogen-associated ligands (single-stranded RNA and unmethylated CpG DNA (CpG), respectively), and that initiates a signaling cascade in which the adaptor MyD88 forms a complex with the kinases IRAK1 and IRAK4 and the E3 ubiquitin ligase TRAF6 (ref. 4) . That leads to the activation of transcription factors, such as the interferon-regulatory factors IRF3, IRF7 and IRF8, STAT3 and STAT5, and NF-κB, which modulate specific genes that drive maturation of the TLR-expressing cells and the production of type I interferons (IFN-α/β) and other proinflammatory molecules 2, 5 . This response slows the spread of infection and recruits the adaptive immune system. MicroRNAs (miRNAs) have emerged as important contributors to the antiviral response 6 . miRNAs are short, noncoding RNAs that incorporate into argonaute (Ago) proteins 7 . miRNAs guide Ago proteins to transcripts with complementary sequences, and, once bound, Ago proteins can prevent expression of the transcript either by blocking translation of the mRNA or by promoting the mRNA's decay 7 .
Profiling of miRNA has identified many miRNAs that are induced by TLR stimulation, such as miR-146 and miR-155, whose expression is upregulated in macrophages and DCs following exposure to unmethylated CpG nucleotides and other TLR ligands [8] [9] [10] .
Although several of the TLR-responsive miRNAs have been shown to propagate or dampen the innate response after initial triggering 9, [11] [12] [13] , it is not well known whether any miRNAs are involved in preconditioning the responsiveness of the host to pathogen infection in the steady state, before infection. Here we set out to investigate this issue. Unexpectedly, we found that miR-126, a miRNA that has been associated mainly with the regulation of vasculogenesis and angiogenesis [14] [15] [16] , controlled the IFN-α/β response to pathogen-associated nucleic acids through regulating the homeostasis and function of plasmacytoid DCs (pDCs). We further found that miR-126 operated in part by regulating another proangiogenic gene, Kdr (which encodes the growth factor receptor VEGFR2), in pDCs. Our work identifies the existence of an endothelial cell pathway that operates in pDCs to control the innate response and assigns a previously unknown function to a clinically targeted receptor and miRNA.
RESULTS
The innate response to nucleic acids requires miR-126
In an effort to understand the relevance of miR-155 in the early interferon response, we injected miR-155-deficient (Mir155 −/− ) mice with the TLR9 agonist CpG-A and measured serum concentrations of IFN-α after 3 h. As a comparison, we injected CpG-A into wild-type mice, as well as mice deficient in miR-126 (Mir126 −/− ), an miRNA that is expressed mainly in endothelial cells and helps to control angiogenesis in the embryo 15, 16 . In both wild-type and Mir155 −/− mice, there was a similar increase in circulating IFN-α after injection of CpG-A ( Fig. 1a) . Unexpectedly, however, Mir126 −/− mice produced less IFN-α than did wild-type or Mir155 −/− mice (Fig. 1a) .
Even at a higher dose of CpG and with analysis over time, there was a significant difference between Mir126 −/− mice and wild-type control mice in IFN-α production (P = 0.001; Supplementary  Fig. 1a ). Moreover, the production of interleukin 6 (IL-6) was also much lower in the absence of miR-126 ( Supplementary Fig. 1b ), which indicated that loss of miR-126 impaired the innate response to unmethylated DNA. To determine whether Mir126 −/− mice were impaired in their response to other TLR stimuli, we challenged those mice, along with the Mir155 −/− and wild-type mice, with the TLR7 agonist R-848 and measured IFN-α 2 h later. Similar to the results we obtained with the TLR9 agonist, Mir126 −/− mice treated with the TLR7 agonist had significantly less circulating IFN-α than did wild-type mice ( Fig. 1b) .
TLR7 and TLR9 mediate the initial sensing of HIV 17, 18 , which triggers the release of IFN-α/β that blocks the infection of cells by HIV 19 . To determine if miR-126 is also required for the sensing of HIV, we gave Mir126 −/− mice an injection of vesicular stomatitis virus (VSV)-pseudotyped, nonreplicating HIV. As expected, in wild-type mice, circulating concentrations of IFN-α rapidly rose after injection, but in the Mir126 −/− mice, circulating IFN-α concentrations were barely above background (Fig. 1c) . In wild-type mice there was enlargement of the lymph nodes ( Fig. 1d) and an overall increase in cellularity, including the number of neutrophils, monocytes and B cells (data not shown). In the Mir126 −/− mice, VSVpseudotyped HIV did not cause enlargement of the lymph nodes or a change in cellularity ( Fig. 1d and data not shown), which provided additional evidence that Mir126 −/− mice did not respond normally to infection.
Wild-type and Mir155 −/− mice given an injection of VSVpseudotyped HIV had few infected cells, as indicated by the lack of cells expressing green florescent protein (GFP), which is encoded by the virus, and measurement of viral integration ( Fig. 1e,f) . In Mir126 −/− mice, there was widespread infection throughout the tissue, which indicated that the production of IFN-α/β was sufficiently diminished by the loss of miR-126 to result in increased cell infection. These data provided clear evidence that Mir126 −/− mice were functionally impaired in their response to stimulation of TLR7 and TLR9 and revealed that miR-126 was required for a normal IFN-α/β response to pathogen-associated nucleic acids.
High expression of miR-126 by pDCs
The expression of miR-126 is reported to be predominately specific to endothelial cells 16 ; however, transcriptional analysis across the hematopoietic system, as well as in fibroblasts, epithelial cells and endothelial cells, indicated that TLR7 and TLR9 were expressed only by macrophages, B cells and DCs and not by endothelial cells or other nonhematopoietic cells ( Supplementary Fig. 2a ). Thus, it was unclear why Mir126 −/− mice had an impaired TLR7 and TLR9 response, so we investigated whether any of the TLR-expressing cells also expressed miR-126.
We isolated B cells, macrophages, CD4 + or CD8 + T cells, CD4 + or CD8 + conventional DCs (cDCs), and pDCs from the spleens of mice. We found high expression of miR-126 only in pDCs, among the hematopoietic cells analyzed ( Fig. 2a ). Expanded analysis of 365 miRNAs across DC subsets revealed that although other miRNAs had a difference in expression among DCs, miR-126 was the only miRNA that was expressed in one subset, the pDCs ( Fig. 2b and Supplementary Fig. 2b ). To confirm those findings, we isolated CD4 + DCs and pDCs and deep sequenced the small RNA fraction of the cells. In support of the results obtained by quantitative PCR analysis, we detected miR-126 in pDCs but not in CD4 + DCs (Fig. 2c,d) . We found that miR-126 was one of the most abundant miRNA in pDCs, with more than 4 × 10 4 'reads' per million, or 5% of the total miRNA pool of the pDCs (Fig. 2c,d) .
To determine if human pDCs also expressed miR-126, we isolated pDCs and cDCs from human peripheral blood by flow cytometry. We extracted total RNA from the cells and measured expression of miR-126, as well as miR-16, miR-21 and miR-142-3p. Whereas the other three miRNAs had similar expression in pDCs and cDCs, miR-126 expression was 12-fold higher in pDCs than in cDCs from human peripheral blood ( Fig. 2e) . pDCs are the first and strongest producers of IFN-α during viral infection because of their steady-state expression of TLR7, TLR9 and IRF7 (ref. 20) . As pDCs were the only TLR7-and TLR9-expressing cells in which we detected miR-126, and pDCs are major IFN-α/β-producing cells 21 , these results suggested that the diminished IFN-α/β response to single-stranded RNA and unmethylated DNA in Mir126 −/− mice may have been due to a defect in pDCs.
Control of pDC homeostasis by miR-126
To investigate how the loss of miR-126 may have affected the innate response to stimulation of the TCR, we examined the frequency of In each of the tissues examined, a consistent pattern emerged in which the frequency and absolute number of pDCs was 50% lower or more in Mir126 −/− mice than in the control mice ( Fig. 3a) . In contrast, there was no change in the frequency of other DC subsets (CD4 + or CD8 + DCs), B cells, T cells, granulocytes or monocytes ( Fig. 3b-d and Supplementary Fig. 3 ). These findings suggested that the impaired response to stimulation via TLR7 and TLR9 in Mir126 −/− mice was due to a specific deficiency in pDCs and not to a general deficiency in cells of the immune system and revealed an important role for miR-126 in pDC homeostasis.
Regulation of pDC survival by miR-126
After pDCs develop in the bone marrow (BM) from myeloid progenitors common to all DCs, they are released into the blood as mature pDCs 20, 22 . In the BM, precursors of macrophages and DCs can differentiate into common DC precursors (CDPs), which can then become npg A r t i c l e s pDCs or precursors of cDCs (pre-cDCs) 22 .
To understand at which stage of pDC development miR-126 may be critical, we isolated common myeloid progenitors (CMPs), CDPs, pDCs and pre-cDCs from the BM and measured miR-126 expression. We found that miR-126 expression increased during differentiation, with maximum expression in pDCs and almost no expression in cDCs ( Fig. 4a) . Flow cytometry analysis indicated that the frequency and number of CMPs and CDPs was normal in Mir126 −/− mice but the number of pDCs was decreased by 30% in the BM (Fig. 4b) .
Since we detected pDCs in Mir126 −/− mice, we speculated that the impaired homeostasis was due to a defect in the replication or survival of pDCs. To assess proliferation, we quantified pDCs positive for the proliferation marker Ki67 and the thymidine analog BrdU in the BM, where pDCs develop. This revealed no difference between Mir126 −/− pDCs and wild-type pDCs in their proliferation rate ( Fig. 4c) , which suggested that loss of miR-126 did not decrease the number of pDCs by reducing their ability to proliferate. We next measured apoptosis of pDCs by staining them with annexin V and the DNA-intercalating dye DAPI, followed by flow cytometry. The ratio of both annexin V-positive and DAPI-positive cells and preapoptotic annexin V-positive and DAPI-negative cells was more than twofold higher among Mir126 −/− pDCs than among wild-type pDCs (Fig. 4d) , which indicated that increased apoptosis was responsible for the reduced number of pDCs in Mir126 −/− mice.
To further understand how pDC homeostasis was impaired in the absence of miR-126, we took advantage of an in vitro model of DC development that uses the cytokine Flt3L to drive DC progenitors to differentiate into DC subsets (including the pDC subset) with molecular and phenotypic profiles similar to those of in vivo DCs 22 . We collected BM from Mir126 −/− mice and their wild-type littermates (as control mice), cultured the BM with Flt3L and monitored DC differentiation over time. After 3 d, there were similar numbers of pDCs in wild-type and Mir126 −/− cultures, as measured by the frequency of CD11c + B220 + mPDCA1 + cells. However, by day 5, there were 40% fewer Mir126 −/− pDCs than wildtype pDCs, and by day 7 the number of Mir126 −/− pDCs was 60% lower than that of wild-type pDCs (Fig. 4e) . There was no statistically significant difference in the number of DC progenitors or cDCs between the wild-type and Mir126 −/− cultures (P = 0.197; data not shown).
We assessed pDC proliferation during in vitro development by dilution of the fluorescent dye eFluor670 and found no difference between Mir126 −/− pDCs and wild-type pDCs (Supplementary Fig. 4) . However, the frequency of pDCs that underwent apoptosis in the cultures containing Flt3L, as measured by staining with annexin V and DAPI, was significantly higher among Mir126 −/− pDCs than among wild-type pDCs (Fig. 4e) . These results recapitulated our A r t i c l e s in vivo findings showing that the reduced number of pDCs in Mir126 −/− mice was due to an increase in the rate of pDC apoptosis and indicated that miR-126 controlled pDC survival.
Normal pDC function requires miR-126
Although there were substantially fewer pDCs in Mir126 −/− mice than in wild-type mice, there were still cells in the Mir126 −/− mice and cultures that expressed pDC markers. To determine if the pDCs that developed without miR-126 were functional, we isolated pDCs from wild-type and Mir126 −/− mice and stimulated matched numbers of cells with CpG-A ex vivo. Whereas wild-type pDCs produced more than 1,000 pg/ml of IFN-α, Mir126 −/− pDCs produced less than 200 pg/ml (Fig. 5a ).
Next we assessed pDC maturation in vivo by giving Mir126 −/− mice or their wild-type littermates (as control mice) an injection of CpG-A. After 3 h, we assessed the expression of CD69, an activation marker, and found that Mir126 −/− pDCs were less activated than were wild-type pDCs (Fig. 5b) . Since pDCs are known to migrate after activation 23, 24 , we investigated their biodistribution in the spleen after injection of CpG. In the steady state, pDCs were located in the T cell zone in both wild-type and Mir126 −/− mice, albeit at a reduced frequency in Mir126 −/− mice (Fig. 5c) . At 3 h after injection of CpG, wild-type pDCs had migrated to the outer marginal zone and formed clusters (Fig. 5c) , as reported before 24 . In contrast, in Mir126 −/− mice, the pDCs remained in the T cell zone after injection of CpG (Fig. 5c) , which further suggested that their function was impaired. These results demonstrated that in addition to controlling pDC survival, miR-126 was necessary for normal pDC function.
Wild-type pDCs restore IFN-a secretion in Mir126 −/− mice The diminished number and function of Mir126 −/− pDCs suggested that this was the reason for the impaired innate response of Mir126 −/− mice. To test that hypothesis, we isolated pDCs from wild-type mice and transferred them into Mir126 −/− mice. In parallel, we gave those recipient mice, as well as additional wild-type and Mir126 −/− mice that received no cells, injection of VSV-pseudotyped HIV and monitored the IFN-α response. In Mir126 −/− mice, there was a small increase in serum IFN-α over time (up to 36 pg/ml), but in Mir126 −/− mice that received wild-type pDCs, IFN-α concentrations were more than 100 pg/ml by 5 h, similar to that of wild-type mice (Fig. 5d ). Together our findings indicated that the diminished innate response in Mir126 −/− mice was due to control of the homeostasis and function of pDCs by miR-126.
Mir126 −/− pDCs have a diminished innate response profile To understand why activation was impaired in miR-126-deficient pDCs, we sorted pDCs from Mir126 −/− mice and their wild-type littermates (as control mice) and did transcriptional profiling. The expression of 253 genes was altered by loss of miR-126, with most of the genes clustering in specific innate immune response pathways, including the tumor-necrosis factor receptor pathway, the NF-κB pathway and the TLR-induced pathway (Fig. 6a) . The expression of both Tlr7 and Tlr9 was significantly lower in Mir126 −/− pDCs (Fig. 6b) , along with that of other key genes that encode viral detectors, such as Dhx58 (which encodes the helicase Lpg2) 25 , Arhgap21 (which encodes the Rho GTPase-activating protein Arhgap21) 3 , Ifih1 (which encodes the RNA helicase Mda5) and Mx2 (which encodes the GTP-binding protein Mx2), all of which are genes expressed by pDCs even in the steady state 26 .
Ccl4 and Ccl3 (which encode the chemokines CCL4 and CCL3, respectively) are expressed by pDCs 27 ; however, Mir126 −/− pDCs had lower expression of both genes than did wild-type pDCs (Fig. 6b) . TNF was another cytokine whose expression was lower in Mir126 −/− pDCs. The expression of Nfkb1 and Nfkb2 (which encode subunits of NF-κB) was also lower in Mir126 −/− pDCs than in wild-type pDCs. Moreover, the expression of Stat3 and Stat5b (which encode key transcription factors involved in TLR signaling and cytokine production) 28 was similarly lower in Mir126 −/− pDCs than in wildtype pDCs. These studies indicated that miR-126 was necessary for pDCs to establish a normal molecular configuration for responding to pathogen-associated nucleic acids. They also provided mechanistic insight into the impaired response of Mir126 −/− pDCs to singlestranded RNA and CpG DNA.
Translation of Tsc1 suppressed by miR-126
We used in silico analysis to 'cross-identify' genes that have a miR-126 target site and encode molecules that participate in an innate Table 1 ). Of note, the mRNA of Tsc1 (which encodes a negative regulator of the kinase mTOR) contained a target for miR-126, and was expressed by pDCs ( Fig. 6c) . Since the mTOR pathway regulates pDC survival 29 and acts together with TLR signaling in pDCs 30 , we investigated whether miR-126 directly regulates Tsc1. We sorted pDCs by flow cytometry from the spleens of Mir126 −/− mice and their wild-type littermates (as control mice) and measured Tsc1 by immunoblot analysis. More Tsc1 was present in Mir126 −/− pDCs than in wild-type pDCs (Fig. 6d) , which suggested that miR-126 decreased the expression of Tsc1 protein in wild-type pDCs. To confirm that the Tsc1 transcript was directly regulated by miR-126, we cloned the 3′ untranslated region (UTR) of Tsc1 downstream of the gene encoding luciferase in a reporter plasmid. We transfected that plasmid into 293T human embryonic kidney cells (which do not express miR-126), along with either a control plasmid or a plasmid expressing miR-126. Cells overexpressing miR-126 had 30% lower luciferase expression than that of cells expressing the control plasmid (Fig. 6e) , which demonstrated that miR-126 directly regulated the abundance of Tsc1. This result indicated that miR-126 controlled a negative regulator of the mTOR pathway and helped to explain the impaired survival and TLR response of pDCs in the absence of miR-126.
Deletion of Kdr is a partial phenocopy of loss of miR-126 Notably, one of the genes whose expression was downregulated in Mir126 −/− pDCs was Kdr, which encodes VEGFR2 (Fig. 6b) . VEGFR2 is a receptor tyrosine kinase that is the main receptor for the growth factor VEGF-A 31 . Kdr is a haploinsufficient gene that is essential for vasculogenesis during fetal development as well as in angiogenesis during wound healing and tumor growth 32 . Studies of VEGFR2 reporter mice have revealed that VEGFR2 is expressed only by endothelial cells in the steady state 33 . However, examination of data from the Immunological Genome Project, which include the transcriptional profiles of 234 types of cells of the immune system 26 , revealed high expression of Kdr on pDCs , whereas its expression was low or undetectable on all other hematopoietic cell types (Fig. 7a) .
To confirm those findings, we assessed the expression of VEGFR2 on the surface of pDCs by flow cytometry. We detected abundant VEGFR2 on B220 + PDCA1 + cells but not on B cells or cDCs in mouse spleen ( Fig. 7b and Supplementary Fig. 5a ). We confirmed that VEGFR2 was also expressed by human pDCs but not cDCs by isolating pDCs and cDCs from human blood and lungs and measuring KDR expression by quantitative PCR. We detected VEGFR2 only in pDCs from tissues in humans as well as mice, and not those isolated from blood (in humans) or the BM (in mice) ( Fig. 7c,d) , which suggested that VEGFR2 expression may be upregulated in pDCs only after they enter a tissue.
We measured VEGFR2 expression on Mir126 −/− pDCs in the spleen and lymph nodes by flow cytometry. Consistent with the diminished abundance of Kdr mRNA (Fig. 6b) , VEGFR2 expression was lower in pDCs in the absence of miR-126 ( Fig. 7e) . Since we found that miR-126 directly regulated Tsc1, we sought to determine whether the mTOR pathway controls VEGFR2 expression in pDCs. To assess this, we cultured total splenocytes from wild-type mice in the presence or absence of the mTOR inhibitor rapamycin, then measured VEGFR2 expression. Rapamycin significantly downregulated VEGFR2 expression in a dosedependent manner (Fig. 7f) . Similar downregulation of VEGFR2 expression occurred in pDCs in vivo when we treated mice with rapamycin (data not shown). These results indicated that miR-126 positively regulated VEGFR2 expression in pDCs and suggested that this may have occurred through control of the mTOR pathway by miR-126. In endothelial cells, signaling through VEGFR2 promotes cell survival 32 . Thus, we hypothesized that VEGFR2 may have a similar role in pDCs. To test our hypothesis, we crossed Itgax-Cre mice, which express Cre recombinase (driven by Itgax, which encodes the common DC marker (integrin α X ) CD11c) in DCs 34 , with mice with loxP-flanked Kdr alleles (Kdr fl/fl mice) to generate mice with deletion of Kdr specifically in DCs (Kdr fl/fl Itgax-Cre mice; Supplementary  Fig. 5b,c) . The frequency of pDCs in the spleen of Kdr fl/fl Itgax-Cre mice was 0.3%, compared with a frequency of ~0.5% in their wildtype (Kdr +/+ Itgax-Cre) littermates (Fig. 7g) ; this represented a 40% reduction of pDCs, comparable to what we observed in Mir126 −/− mice. Moreover, consistent with our finding that VEGFR2 was not expressed on BM pDCs, the number of pDCs in the BM was not altered in Kdr fl/fl Itgax-Cre mice (Supplementary Fig. 5d ).
Finally, we examined the IFN-α response in the mice with DCspecific VEGFR2 deficiency. We gave Kdr fl/fl Itgax-Cre mice and their wild-type (Kdr +/+ Itgax-Cre) littermates an injection of R-848 or CpG-A and measured serum concentrations of IFN-α. After injection of either ligand, there was a significantly less IFN-α in Kdr fl/fl Itgax-Cre mice than in the wild-type (Kdr +/+ Itgax-Cre) control mice (Fig. 7h) , which partially recapitulated the impaired IFN-α/β response observed in Mir126 −/− mice. These studies provided evidence of the importance of VEGF signaling in the homeostasis and function of pDCs and suggested that miR-126 regulated pDCs at least in part through its control of VEGFR2 expression ( Supplementary Fig. 6 ).
DISCUSSION
Our studies have revealed that miR-126 regulated the innate response to pathogen-associated nucleic acids. This finding was unanticipated, as miR-126 has been associated mainly with control of angiogenesis [14] [15] [16] . Our initial observation was that Mir126 −/− mice produced significantly less IFN-α in response to single-stranded RNA and CpG DNA, as well as to HIV, than did wild-type mice, and that this increased host permissiveness to viral infection. We concluded that the defect was due to miR-126's control of the homeostasis and function of pDCs, because pDCs were the only TLR7-and TLR9-expressing cells that expressed miR-126 and the frequency of pDCs was reduced in the absence of miR-126. Moreover, we specifically showed that miR-126-deficient pDCs had a diminished activation capacity. pDCs were only fully discovered just over a decade ago 23, 35, 36 , and the molecular underpinnings that control their homeostasis and function are still mostly unknown 20 . Our transcriptional profiling indicated that in the absence of miR-126, pDCs exhibited lower expression of genes encoding molecules crucial for the innate recognition and response process. The expression of both Tlr7 and Tlr9 was decreased, as was that of genes encoding key transcription factors and signaling molecules involved in the expression of IFN-α/β and other proinflammatory cytokines, such as Nfkb1, Stat3 and Arhgap21 (refs. 3, 37) . Although the difference in expression of some of these genes was modest, the coordinated reduction in the expression of so many factors that participate in the same pathways is what probably resulted in the substantial impairment in IFN-α production from Mir126 −/− pDCs. As the expression of those genes was reduced in nonactivated pDCs, our results indicated that miR-126 functioned in the steady state to control the readiness of pDCs to sense and respond to pathogens. In addition to controlling the IFN-α/β response through the regulation of key innate pathways, miR-126 also functioned by regulating pDC homeostasis. Although it seemed that pDC differentiation was initiated even in the absence of miR-126, we found that miR-126 controlled the frequency of pDCs by controlling the survival of pDCs. The identification of a molecule that controls pDC survival is a notable finding, as very little is known about what controls the lifespan of a pDC in the steady state 20 . The phosphatidylinositol-3-OH kinase-mTOR pathway has a role in the survival of human pDCs in vitro 29 . However, since that is a commonly used survival pathway 38 , the discovery of upstream factors, particularly ones that are unique to pDCs among hematopoietic cells, is relevant as it provides a potential target for controlling the survival and function of pDCs.
Our data indicated that miR-126 was able to directly suppress the abundance of Tsc1. Because Tsc1 is a negative regulator of mTOR 38 , miR-126-mediated suppression of Tsc1 would allow enhanced signaling through this pathway and enhance pDC survival. In addition to the role of mTOR in cell survival, it also acts together with components of the TLR9 pathway to induce IFN-α/β expression 30, 39 . Thus, miR-126-mediated suppression of Tsc1 would also serve to enhance the TLR9 response and would further explain the impaired IFN-α/β response in the absence of miR-126.
We also found that pDCs had high expression of VEGFR2 and that VEGFR2 signaling contributed to the homeostasis and function of pDCs. VEGFR2 expression was lower in the absence of miR-126, which indicated that miR-126 positively regulated VEGFR2 expression in pDCs. We found that mTOR positively regulated VEGFR2 expression. Thus, it is likely that miR-126 suppression of Tsc1, which would increase mTOR activity 38 , was how miR-126 controlled the abundance of VEGFR2. Since VEGFR2 signaling also negatively regulates Tsc1, the miR-126-VEGFR2 axis represents a feed-forward mechanism for enhancing mTOR activity and increasing pDC survival and IFN-α/β production.
VEGFR2 is essential for vascularization, and many tumor cell types produce VEGF-A (the ligand for VEGFR2) to promote angiogenesis. This may explain why large numbers of pDCs are found in some solid tumors 40 . Many drugs have been designed to block VEGFR2 signaling, such as bevacizumab (Avastin); these are used for cancer therapy as well as for the treatment of macular degeneration 41 . Our results suggest that the effect of such drugs on innate immunity should be assessed, as they may have unintended consequences on pDCs.
Our study has identified an additional function for the miR-126-VEGFR2 pathway and a previously unknown regulator of the innate response to pathogen-associated RNA and DNA. Since pDCs have an important role in autoimmunity [42] [43] [44] [45] [46] , future studies should investigate whether dysregulated expression of miR-126 is associated with the etiology of any of those conditions. It has already been reported that miR-126 is present in the blood of patients with systemic lupus erythematosus 47 , but more detailed analysis is necessary. Given that both the VEGF pathway and now miRNAs are targets that can be treated with drugs 41, 48 , our findings have potential implications for the treatment of cancer and autoimmune disease.
METHODS
Methods and any associated references are available in the online version of the paper.
